๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kolkata
Clinical trial register · India

Clinical Trials in Kolkata

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1125 matching records held by the registry are in this view. Synced 22 Sep 2026, 03:16 UTC
1125
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
Kolkata 54 Delhi 40 Bangalore 39 New Delhi 38 Mumbai 37
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca54 Bristol-Myers Squibb12 Janssen Research & Development, LLC11 Pfizer10 Sanofi6 Clear sponsor filter
Site location
Kolkata54 Delhi40 Bangalore39 New Delhi38 Mumbai37
All 76 locations
Target enrolment
to
54 of 1125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
AstraZeneca
Phase 3
1,072
Kolkata
2026-09-01
Not yet open
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
1,500
Bangalore, Indore, Kolkata, Nagpur, Pune, Siliguri, Visakhapatnam
2026-08-21
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
AstraZeneca
Phase 3
2,500
Bhubaneswar, Coimbatore, Hyderabad, Indore, Jaipur, Jodhpur, Kochi, Kolkata
2026-08-19
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca
Phase 3
915
Kolkata, Kottayam, Nashik, Navi Mumbai, New Delhi
2026-07-16
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca
Phase 3
2,130
Ahmedabad, Bhubaneswar, Hyderabad, Kolkata, Mohali, Mumbai, New Delhi, Varanasi
2026-02-03
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Bhubaneswar, Chennai, Delhi, Dhanvantari Nagar, Kolkata, Nagpur, Nashik, Surat
2025-12-29
Active, closed
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
NCT06851806Respiratory Syncytial Virus (RSV)
AstraZeneca
Not applicable
21
Hyderabad, Jhฤnsi, Kanpur, Kolkata, Mysore, Nagpur, Pune, Vidyanagar, Hubballi
2025-12-10
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
AstraZeneca
Phase 3
1,100
Delhi, Hyderabad, Kolhฤpur, Kolkata, Mumbai, Nashik, Surat
2025-12-04
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
AstraZeneca
Phase 3
400
Bangalore, Kolkata, Mumbai, Nashik, New Delhi
2025-10-31
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Belagavi, Delhi, Hyderabad, Kolkata, Mumbai
2025-08-07
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Bangalore, Belagavi, Hyderabad, Kolkata, Madurai, Mumbai, New Delhi, Pune
2025-03-03
Recruiting
A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 3
840
Ansฤrinagar, Bangalore, Delhi, Hyderabad, Kolkata, Mumbai, Varanasi
2025-03-01
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-18
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
AstraZeneca
Phase 3
620
Dehradun, Delhi, Kanpur, Kolkata, Mumbai, Vadodara, Varanasi
2024-08-12
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
AstraZeneca
Phase 3
1,018
Delhi, Gurugram, Kolkata, Nashik, Surat, Thiruvananthapuram
2024-08-07
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Ahmedabad, Dehradun, Delhi, Gurugram, Hyderabad, Kolkata, Lucknow, Mumbai
2024-06-20
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
675
Chennai, Dwฤrka, Jaipur, Kolkata, Marg Jaipur, Nagpur, Nashik, New Delhi
2024-04-11
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
2,554
Bangalore, Belagavi, Calicut, Chennai, Coimbatore, Dehradun, Hyderabad, Kolkata
2024-03-29
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Bengaluru, Hyderabad, Jaipur, Kanpur, Kochi, Kolkata, Lucknow, Madurai
2023-12-14
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Delhi, Kolkata, Mumbai, Mysuru, New Delhi, Varanasi
2023-12-04
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
AstraZeneca
Phase 3
625
Calicut, Chennai, Jaipur, Kochi, Kolkata, Kottayam, Marg Jaipur, Mohali
2023-11-23
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Bangalore, Calicut, Kanpur, Kolkata, Nagpur, New Delhi, Pune, Vadodara
2023-11-21
Rows per page Showing 1–25 of 54
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-india/city/kolkata

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.